
|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
2006: A Regulatory Odyssey
The regulatory environment is changing and is starting to sweep away some of the commandments on which we have relied, and to change others almost unrecognizably. To make the transition, FDA will have to reinvent itself and industry will have to rethink the way we develop and manage our processes.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
CDER?s Division of Post-Marketing Evaluation for Quality AssessmentAdvertisement
Advertisement
Advertisement
Trending on LCGC International
1
The Silent Crisis: Can The Demise of Chromatography Teaching in Universities Be Reversed?
2
Conference Talk: Current Trends in Separation Science
3
GC-MS Reveals Regional Flavor and Aroma Shifts in Oranges
4
LC-MS Reveals Food-Linked Stress Proteins
5




